C4 Therapeutics reported a 53% response rate for simsidamide at its 100 micrograms recommended Phase II dose in heavily pretreated multiple myeloma patients, with two MRD negative CRs.
CCCC · C4 Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 34%
- Last earnings
- May 26, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Oct 2020 to Nov 2026
Latest documents
C4 Therapeutics reported a 53% overall response rate at the highest simsidamide dose in 72 first-in-human patients. Enrollment is expected to finish in the first quarter of 2027, with combination data guided for mid-year 2027.
Cemsidomide Phase 2 MOMENTUM enrollment is expected to complete in the first quarter of 2027, with initial investigator-assessed overall response rate data expected in the second half of 2027. CFT8919 will not advance outside Greater China at this time.
C4 Therapeutics expects cash to fund operations to the end of 2028, while cemsidomide’s Phase 2 MOMENTUM enrollment is on track to complete in the first quarter of 2027; third-quarter 2026 revenue was $8.5 million.
C4 Therapeutics reported cemsidomide immune activation in 62 RRMM patients and biomarker findings from two patients; the 75 µg dose was declared safe, and cohorts at 75 µg and 100 µg are advancing, with data expected in mid-2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| upfront cash payment | $20M | the second quarter of 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CCCC
this stock
C4 Therapeutics, Inc.
|
$325.67M | +29.8% | +1.0% | — | 35.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 23
C4 Therapeutics reported a 53% response rate for simsidamide at its 100 micrograms recommended Phase II dose in heavily pretreated multiple myeloma patients, with two MRD negative CRs.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CCCC | -10.1% | -19.0% | -42.9% | -26.4% | +29.8% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -1.6% | -9.7% | -33.7% | -17.7% | +28.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.